These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15367228)

  • 1. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant.
    Yen EF; Hardinger K; Brennan DC; Woodward RS; Desai NM; Crippin JS; Gage BF; Schnitzler MA
    Am J Transplant; 2004 Oct; 4(10):1703-8. PubMed ID: 15367228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.
    Kadatz M; Gill JS; Gill J; Formica RN; Klarenbach S
    J Am Soc Nephrol; 2020 Jan; 31(1):218-228. PubMed ID: 31704739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Medicare's coverage of immunosuppression medications for kidney transplant recipients.
    Page TF; Woodward RS
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):435-44. PubMed ID: 19817527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Income-related disparities in kidney transplant graft failures are eliminated by Medicare's immunosuppression coverage.
    Woodward RS; Page TF; Soares R; Schnitzler MA; Lentine KL; Brennan DC
    Am J Transplant; 2008 Dec; 8(12):2636-46. PubMed ID: 19032227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of extended coverage of immunosuppressive medications by medicare on the survival of cadaveric renal transplants.
    Woodward RS; Schnitzler MA; Lowell JA; Spitznagel EL; Brennan DC
    Am J Transplant; 2001 May; 1(1):69-73. PubMed ID: 12095042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
    Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of lifetime immunosuppression coverage for kidney transplant recipients.
    Page TF; Woodward RS
    Health Care Financ Rev; 2008; 30(2):95-104. PubMed ID: 19361119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending Medicare immunosuppressive medication coverage.
    Beaubrun AC
    J Health Care Poor Underserved; 2012 Feb; 23(1):20-7. PubMed ID: 22643460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Medicare's lifetime immunosuppression coverage on racial disparities in kidney graft survival.
    Page TF; Woodward RS; Brennan DC
    Am J Transplant; 2012 Jun; 12(6):1519-27. PubMed ID: 22335186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Payment for immunosuppression after organ transplantation. American Society of Transplantation.
    Kasiske BL; Cohen D; Lucey MR; Neylan JF
    JAMA; 2000 May; 283(18):2445-50. PubMed ID: 10815094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.
    Gharibi Z; Ayvaci MUS; Hahsler M; Giacoma T; Gaston RS; Tanriover B
    Transplantation; 2017 Jun; 101(6):1234-1241. PubMed ID: 27379555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.
    Tanriover B; Stone PW; Mohan S; Cohen DJ; Gaston RS
    Clin J Am Soc Nephrol; 2013 Jul; 8(7):1258-66. PubMed ID: 23559679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis.
    Abecassis MM; Seifeldin R; Riordan ME
    Transplant Proc; 2008 Jun; 40(5):1443-5. PubMed ID: 18589126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Implications of New National Allocation Policy for Deceased Donor Kidneys in the United States.
    Smith JM; Schnitzler MA; Gustafson SK; Salkowski NJ; Snyder JJ; Kasiske BL; Israni AK
    Transplantation; 2016 Apr; 100(4):879-85. PubMed ID: 26784114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The financial impact of immunosuppressant expenses on new kidney transplant recipients.
    Gordon EJ; Prohaska TR; Sehgal AR
    Clin Transplant; 2008; 22(6):738-48. PubMed ID: 18673373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An (ongoing) shortsighted view on transplant coverage policy.
    Zumoff R
    Nephrol News Issues; 2012 Mar; 26(3):8, 10. PubMed ID: 22479970
    [No Abstract]   [Full Text] [Related]  

  • 17. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
    Orme ME; Jurewicz WA; Kumar N; McKechnie TL
    Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients.
    Lewis RL; Canafax DM; Pettit KG; DiCesare J; Kaniecki DJ; Arnold RJ; Roberts MS
    Transplant Proc; 1996 Aug; 28(4):2214-7. PubMed ID: 8769203
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-related immunosuppressive medication nonadherence among kidney transplant recipients.
    Evans RW; Applegate WH; Briscoe DM; Cohen DJ; Rorick CC; Murphy BT; Madsen JC
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2323-8. PubMed ID: 20847093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.